SPAC Daily: 2 DAs Highlight a Quiet Market

by | Sep 29, 2022

It’s been a rather quiet going in SPAC land amidst a very nasty broader equity market (save for extension votes of course). Today the “highlight” saw two new definitive agreements hit the tape, one in the morning and one post close.

  • Consumer Direct Holdings is going public via DTRT Health Acquisition (DTRT) in a $681M EV deal that includes $150M of debt financing
  • YS Biopharma, a Chinese rabies vaccine company, struck a deal with Summit Healthcare Acquisition Corp. (SMIH)

That brings us to 6 new DAs on the week, which is almost shocking considering the tumult in equities. Issuance is still quiet for a few weeks now, though rumor has it two SPACs will be pricing tonight including one from SPAC veterans dMY. So look out for that.

Elsewhere in SPACs

  • Northern Lights Acquisition (NLIT) and Safe Harbor Financial finally closed their SPAC deal 3 months after the vote. SHFS closed down 15% on its first day of trading to close at $8.74
  • Liberty Media Acquisition Corporation (LMACA) filed a preliminary proxy to move its liquidation date up to 2022 (perhaps to avoid the excise tax). Big sponsor goes down
  • Brilliant Acquisition Corp. (BRLI) to double up to 1,012,000 (or the equivalent of 40% of all outstanding shares and rights in connection with its merger vote
  • Atlantic Avenue Acquisition (ASAQ) adjourned its planned extension vote out till 10/4
  • Executive Partnering Corp. (ENPC) set a 10/20 date for its Granite Ridge Vote

SPAC Calendar

Today’s Movers

Biggest Gainers

Biggest Losers

Recent Analysis

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.